Page 521 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.3. Comparison between watchful waiting and radiation therapy (continued)
Author, Year Study name Comparison Outcome Followup Sample size Results Factors included in the
[Pubmed ID] /Database definition/ (yr) per group model
measurement
Study design instrument
Stattin 223 NPCRSFS RT vs. Death from Median surveillance: HR=0.68 (0.57, 0.82) Age at diagnosis,
2010 surveillance any cause, followup= 2021 comorbidity, socioeconomic
20562373 data obtained 8.2 yr RT: 1429 group, risk group.
from the (IQR=7.1-
Retrospective Cause of 9.7 yr)
cohort Death
Register or
review of
death
certificates
Elliott 218 CaPSURE BT vs. WW Treatment for Median BT: 799 Crude stricture rates: 14/799 Age at treatment, clinical T
2007 urethral 2.7 yr WW: 378 (1.8%) in patients received BT; stage, Gleason score, PSA
17570425 stricture (range 3 4/378 (1.1%) in patients at diagnosis, clinical risk
identified by days to received WW. stratification, BMI, urinary
Retrospective study 10.9 yr) condition history,
cohort abstracted HR=1.68 (0.46, 6.14), p=0.43 comorbidity count, race,
hospital marital status, education,
records household income
includes (ICD
codes)*
EBRT vs. EBRT: 645 Crude stricture rates: 11/645 Age at treatment, clinical T
WW WW: 378 (1.7%) in patients received stage, Gleason score, PSA
EBRT; 4/378 (1.1%) in patients at diagnosis, clinical risk
received WW. stratification, BMI, urinary
condition history,
HR=1.77 (0.48, 6.55), p=0.39 comorbidity count, race,
marital status, education,
household income

C-178